Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.24 Insider Own0.02% Shs Outstand126.62M Perf Week-3.81%
Market Cap95.20M Forward P/E- EPS next Y-0.26 Insider Trans-66.61% Shs Float125.28M Perf Month12.55%
Income-29.83M PEG- EPS next Q-0.07 Inst Own19.33% Short Float / Ratio5.09% / 17.47 Perf Quarter-5.26%
Sales0.00M P/S- EPS this Y-19.05% Inst Trans-14.05% Short Interest6.37M Perf Half Y-19.25%
Book/sh0.78 P/B0.97 EPS next Y-4.00% ROA-26.12% Target Price4.75 Perf Year1.31%
Cash/sh0.75 P/C1.01 EPS next 5Y- ROE-26.86% 52W Range0.50 - 1.39 Perf YTD43.77%
Dividend- P/FCF- EPS past 5Y54.50% ROI-30.36% 52W High-45.34% Beta1.21
Dividend %- Quick Ratio28.35 Sales past 5Y0.00% Gross Margin- 52W Low51.96% ATR0.05
Employees11 Current Ratio28.35 Sales Q/Q- Oper. Margin0.00% RSI (14)56.55 Volatility6.87% 7.51%
OptionableYes Debt/Eq0.00 EPS Q/Q21.80% Profit Margin- Rel Volume0.67 Prev Close0.74
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume364.65K Price0.76
Recom1.00 SMA206.70% SMA507.64% SMA200-7.17% Volume243,184 Change2.25%
Date Action Analyst Rating Change Price Target Change
Jan-26-18Initiated Maxim Group Buy $2
Nov-20-23 08:30AM
Nov-13-23 09:00AM
Nov-09-23 09:00AM
Oct-30-23 01:00PM
Oct-11-23 08:30AM
09:25AM Loading…
Sep-18-23 09:25AM
Aug-23-23 08:00AM
Aug-14-23 08:30AM
Aug-08-23 09:00AM
Jul-20-23 09:15AM
Jul-13-23 04:15PM
Jul-12-23 09:00AM
Jul-10-23 09:15AM
Jul-06-23 09:28PM
09:15AM Loading…
Jun-28-23 01:03PM
Jun-27-23 09:15AM
Jun-22-23 04:15PM
Jun-21-23 01:48PM
Jun-14-23 09:15AM
Jun-12-23 09:15AM
Jun-01-23 09:10AM
May-23-23 07:00AM
May-15-23 09:10AM
May-11-23 09:00AM
May-09-23 09:15AM
Apr-27-23 09:15AM
11:00AM Loading…
Mar-30-23 11:00AM
Mar-22-23 04:05PM
Mar-21-23 01:19PM
Mar-15-23 09:25AM
Feb-23-23 09:15AM
Feb-13-23 09:15AM
Jan-25-23 09:15AM
Dec-07-22 08:00AM
Nov-07-22 04:00PM
Nov-01-22 09:15AM
Oct-25-22 09:15AM
Oct-24-22 09:15AM
Oct-21-22 10:26AM
Sep-07-22 09:00AM
Aug-22-22 09:30AM
Aug-18-22 09:30AM
Aug-08-22 04:30PM
Jul-28-22 09:00AM
Jul-13-22 06:56PM
Jul-11-22 05:25PM
Jun-02-22 04:05PM
May-18-22 09:30AM
May-14-22 08:55AM
May-09-22 04:05PM
Apr-27-22 09:30AM
Apr-20-22 09:30AM
Mar-23-22 09:30AM
Mar-08-22 09:15AM
Feb-28-22 04:15PM
Feb-07-22 05:30AM
Jan-27-22 09:30AM
Jan-18-22 09:30AM
Dec-22-21 09:30AM
Dec-16-21 09:00AM
Dec-06-21 09:15AM
Dec-05-21 06:38AM
Nov-24-21 09:30AM
Nov-15-21 09:30AM
Oct-21-21 09:30AM
Sep-30-21 09:30AM
Sep-13-21 05:47PM
Sep-10-21 01:48PM
Sep-07-21 05:20PM
Sep-02-21 09:30AM
Aug-25-21 04:11PM
Aug-13-21 09:30AM
Aug-05-21 09:30AM
Jul-15-21 09:00AM
Jul-09-21 10:54AM
Jul-07-21 09:30AM
Jun-16-21 09:00AM
Jun-14-21 06:13PM
Jun-11-21 09:00AM
Jun-09-21 09:00AM
Jun-08-21 01:33AM
Jun-07-21 09:00AM
Jun-01-21 04:39PM
May-27-21 01:30PM
May-21-21 09:00AM
May-14-21 09:15AM
May-11-21 09:30AM
Apr-30-21 09:30AM
Apr-08-21 09:30AM
Mar-31-21 09:30AM
Mar-30-21 09:40AM
Mar-22-21 08:30AM
Mar-11-21 09:30AM
Mar-01-21 09:55AM
Feb-25-21 09:00AM
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEAVER GREGORY LFormer EVP, CFO, & DirectorNov 15Sale0.6550,00032,50055Nov 17 04:01 PM